Literature DB >> 12552566

Phenotypic cellular characterization of an ataxia telangiectasia patient carrying a causal homozygous missense mutation.

Sandra Angèle1, Anthony Laugé, Marie Fernet, Norman Moullan, Pierre Beauvais, Jérôme Couturier, Dominique Stoppa-Lyonnet, Janet Hall.   

Abstract

Most disease-causing mutations in Ataxia telangiectasia (AT) patients correspond to truncating mutations in the ATM gene with very few cases of AT patients carrying two missense sequence alterations being reported. The cellular phenotype of a lymphoblastoid cell line established from an AT patient (AT173) who showed classical clinical AT features, and carried two homozygous missense alterations, the 378T>A variant and 9022C>T located within the ATM kinase domain, has been characterized. ATM mRNA was detectable and the ATM protein level was approximately 50% of that seen in normal cell lines. Functional analysis of this protein revealed a total absence of ATM kinase activity measured either in vitro or in vivo, before and after exposure to ionizing radiation. The AT173 cell line was hypersensitive to ionizing radiation and exhibited a G1 cell cycle arrest defect and an accumulation of cells in G2 phase of the cell cycle after irradiation, a response that is identical to that seen in AT cell lines carrying truncating mutations. These phenotypic features strongly suggest that the 9022C>T (R3008C) missense mutation is the disease-causing mutation and that the presence of ATM protein is not always predictive of a normal cellular phenotype. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552566     DOI: 10.1002/humu.9107

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  9 in total

1.  Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations.

Authors:  Virginie Jacquemin; Guillaume Rieunier; Sandrine Jacob; Dorine Bellanger; Catherine Dubois d'Enghien; Anthony Laugé; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

Review 2.  Molecular pathology of ataxia telangiectasia.

Authors:  A M R Taylor; P J Byrd
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

3.  IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation.

Authors:  Sanghoon Lee; Charlotte Andrieu; Frédéric Saltel; Olivier Destaing; Jessie Auclair; Véronique Pouchkine; Jocelyne Michelon; Bruno Salaun; Ryuji Kobayashi; Pierre Jurdic; Elliott D Kieff; Bakary S Sylla
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

4.  The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents.

Authors:  A Stray-Pedersen; T Jónsson; A Heiberg; C R Lindman; E Widing; I S Aaberge; A L Borresen-Dale; T G Abrahamsen
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

5.  Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours.

Authors:  A Reiman; V Srinivasan; G Barone; J I Last; L L Wootton; E G Davies; M M Verhagen; M A Willemsen; C M Weemaes; P J Byrd; L Izatt; D F Easton; D J Thompson; A M Taylor
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

6.  Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers.

Authors:  M Fernet; N Moullan; A Lauge; D Stoppa-Lyonnet; J Hall
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

7.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

8.  A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C>A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity.

Authors:  Kotoka Nakamura; Francesca Fike; Sara Haghayegh; Rachel Saunders-Pullman; Angelika J Dawson; Thilo Dörk; Richard A Gatti
Journal:  Mol Genet Genomic Med       Date:  2014-03-13       Impact factor: 2.183

9.  ATM polymorphisms as risk factors for prostate cancer development.

Authors:  S Angèle; A Falconer; S M Edwards; T Dörk; M Bremer; N Moullan; B Chapot; K Muir; R Houlston; A R Norman; S Bullock; Q Hope; J Meitz; D Dearnaley; A Dowe; C Southgate; A Ardern-Jones; D F Easton; R A Eeles; J Hall
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.